Literature DB >> 12351146

Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.

David W Hein1.   

Abstract

Aromatic and heterocyclic amines require metabolic activation to electrophilic intermediates that initiate carcinogenesis. N-Acetyltransferase 1 (NAT1) and 2 (NAT2) are important enzymes in the biotransformation of these carcinogens and exhibit genetic polymorphism. Human NAT1 and NAT2 alleles are listed at: http://www.louisville.edu/medschool/pharmacology/NAT.html by an international gene nomenclature committee. The high frequency of the NAT1 and NAT2 acetylation polymorphisms in human populations together with ubiquitous exposure to aromatic and heterocyclic amines suggest that NAT1 and NAT2 acetylator genotypes are important modifiers of human cancer susceptibility. For cancers in which N-acetylation is a detoxification step such as aromatic amine-related urinary bladder cancer, NAT2 slow acetylator phenotype is at higher risk. Multiple studies have shown that the urinary bladder cancer risk is particularly high in the slowest NAT2 acetylator phenotype or genotype (NAT2(*)5). In contrast, for cancers in which N-acetylation is negligible and O-acetylation is an activation step such as for heterocyclic amine-related colon cancer, NAT2 rapid acetylator phenotype is at higher risk. Although studies have found associations between NAT1 genotype and various cancers, the findings are less consistent and are not well understood. Since cancer risk requires exposure to aromatic and/or heterocyclic amine carcinogens modified by NAT1 and/or NAT2 acetylator genotype, the results from human epidemiology studies are dependent upon the quality and accuracy of the exposure assessment and genotype determination. Conclusions require understanding the relationship between genotype and phenotype, as well as the role of genetic variation in carcinogen metabolism, DNA repair, and host susceptibility. Investigations have been carried out in rapid and slow acetylator rodent models in which both exposure and genetic variability are tightly controlled. Human NAT1 and NAT2 alleles have been characterized by recombinant expression to further understand the effects of nucleotide polymorphisms on function and phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351146     DOI: 10.1016/s0027-5107(02)00153-7

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  148 in total

1.  Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer.

Authors:  Wei Tang; Yi-Ping Fu; Jonine D Figueroa; Núria Malats; Montserrat Garcia-Closas; Nilanjan Chatterjee; Manolis Kogevinas; Dalsu Baris; Michael Thun; Jennifer L Hall; Immaculata De Vivo; Demetrius Albanes; Patricia Porter-Gill; Mark P Purdue; Laurie Burdett; Luyang Liu; Amy Hutchinson; Timothy Myers; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina Garcia-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Jarmo Virtamo; David J Hunter; Joseph F Fraumeni; Stephen J Chanock; Debra T Silverman; Nathaniel Rothman; Ludmila Prokunina-Olsson
Journal:  Hum Mol Genet       Date:  2012-01-06       Impact factor: 6.150

2.  Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk.

Authors:  Monika Eichholzer; Sabine Rohrmann; Aline Barbir; Silke Hermann; Birgit Teucher; Rudolf Kaaks; Jakob Linseisen
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

3.  Glucocorticoid receptor-mediated transcriptional regulation of N-acetyltransferase 1 gene through distal promoter.

Authors:  Barbara Bonamassa; Yongjie Ma; Dexi Liu
Journal:  AAPS J       Date:  2012-05-30       Impact factor: 4.009

4.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

Authors:  Montserrat García-Closas; Núria Malats; Debra Silverman; Mustafa Dosemeci; Manolis Kogevinas; David W Hein; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Gemma Castaño-Vinyals; Meredith Yeager; Robert Welch; Stephen Chanock; Nilanjan Chatterjee; Sholom Wacholder; Claudine Samanic; Montserrat Torà; Francisco Fernández; Francisco X Real; Nathaniel Rothman
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

Review 5.  Cytochrome P450 humanised mice.

Authors:  Frank J Gonzalez
Journal:  Hum Genomics       Date:  2004-05       Impact factor: 4.639

6.  Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.

Authors:  Etienne Patin; Luis B Barreiro; Pardis C Sabeti; Frédéric Austerlitz; Francesca Luca; Antti Sajantila; Doron M Behar; Ornella Semino; Anavaj Sakuntabhai; Nicole Guiso; Brigitte Gicquel; Ken McElreavey; Rosalind M Harding; Evelyne Heyer; Lluis Quintana-Murci
Journal:  Am J Hum Genet       Date:  2006-01-13       Impact factor: 11.025

7.  The relationship between the NAT2 phenotype polymorphism and predisposition to suicide in ethnic populations.

Authors:  L A Radkevich; K S Gyul'azizova; I S Nikolaeva; D S Nechaev; I S Soshinskii; E N Krylov; L A Piruzyan
Journal:  Dokl Biochem Biophys       Date:  2005 Sep-Oct       Impact factor: 0.788

8.  Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes.

Authors:  Mark A Doll; David W Hein
Journal:  Arch Toxicol       Date:  2017-05-17       Impact factor: 5.153

9.  Effect of rapid human N-acetyltransferase 2 haplotype on DNA damage and mutagenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline (MeIQx).

Authors:  Kristin J Metry; Jason R Neale; Mark A Doll; Ashley L Howarth; J Christopher States; W Glenn McGregor; William M Pierce; David W Hein
Journal:  Mutat Res       Date:  2009-12-11       Impact factor: 2.433

Review 10.  Biomarkers in Occupational Asthma.

Authors:  Javier Dominguez-Ortega; Pilar Barranco; Rosa Rodríguez-Pérez; Santiago Quirce
Journal:  Curr Allergy Asthma Rep       Date:  2016-09       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.